Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 4/20 | 0.33 |
| ▸ | IP6K3 | Q96PC2 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5291514 | 0.98 | LMNA (0.39) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5298071 | 0.84 | MAOB (0.39) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2920597 | 0.84 | CA2 (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5288050 | 0.83 | CYP3A4 (0.44) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1027461 | 0.75 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2KDM4EIP6K1IP6K3 | |
| SCHEMBL8772908 | 0.74 | ALDH1A1 (0.37) | LMNASMN1; SMN2KDM4EIP6K1IP6K3 | |
| SCHEMBL11210719 | 0.74 | LMNA (0.39) | LMNACA12CA1CA2CA3 | |
| SCHEMBL7155004 | 0.74 | ALDH1A1 (0.40) | SMN1; SMN2KDM4EIP6K1IP6K3IP6K2 | |
| Hydrochloric Acid SCHEMBL5697360 | 0.74 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2KDM4EIP6K1IP6K3 | |
| SCHEMBL7002086 | 0.73 | LOXL2 (0.42) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007016208-A2 | 1,2-BENZISOXAZOLE-3-METHANE-SULFONIC ACID AMMONIUM SALT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-08 | — | — | WO | claimed |
| WO-2005030738-A1 | IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE PREPARATION OF ZONISAMIDE | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-04-07 | — | — | WO | claimed |
| US-7745471-B2 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | CHEMAGIS LTD. (IL) | 2010-06-29 | — | — | US | disclosed |
| US-7745471-B2 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | CHEMAGIS LTD. (IL) | 2010-06-29 | — | — | US | disclosed |
| WO-2007016209-A2 | PURE 1,2-BENZISOXAZOLE-3-METHANE-SULFONIC ACID SODIUM SALT AND PURIFICATION PROCESS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016208-A2 | 1,2-BENZISOXAZOLE-3-METHANE-SULFONIC ACID AMMONIUM SALT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-08 | — | — | WO | disclosed |
| EP-1682522-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | Wockhardt Limited (IN) | 2006-07-26 | — | — | EP | disclosed |
| US-20060014814-A1 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | CHEMAGIS LTD. (IL) | 2006-01-19 | — | — | US | disclosed |
| US-20060014814-A1 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | CHEMAGIS LTD. (IL) | 2006-01-19 | — | — | US | disclosed |
| WO-2005044808-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | WOCKHARDT LIMITED (IN) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014814-A1 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | ZP1, CA3, CYP4Z1 | LMNA 3346/4885CA12 585/4885CA1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.